|Articles|January 21, 2020

CureDuchenne Joins Vivli

CureDuchenne has announced that they will contribute patient-level clinical data for treating muscular dystrophy to the Vivli platform. The data will supplement existing studies that are available to request on the Vivli platform and be available to other researchers around the world.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients
September 12th 2025
Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
September 11th 2025
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025

Trending on Applied Clinical Trials Online

Latest NIMBLE Study Results Highlight Progress in gMG Research

Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients

Q&A: Strategies for Successful Global Clinical Trial Delivery

Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients

© 2025 MJH Life Sciences^®

All rights reserved.